Schwalmstadt-Treysa, Germany – A recent seminar hosted by Hephata-MVZ offered valuable insights into the current state of multiple sclerosis (MS) treatment and ongoing research, providing hope for individuals living with this chronic autoimmune disease. The event, held on February 20, 2026, drew approximately 30 patients and their families, fostering a space for education and open dialogue with medical experts.
Multiple sclerosis affects the central nervous system, disrupting the communication between the brain and the body. Understanding the complexities of MS, including its varied presentation and progression, is crucial for effective management and improved quality of life. Hephata-MVZ’s seminar aimed to address these needs, presenting the latest advancements in diagnosis and therapy.
Understanding the Challenges of Multiple Sclerosis
During the seminar, Dr. Sirous Javidi, a neurologist specializing in sleep medicine and epileptology, explained that MS occurs when the body’s immune system mistakenly attacks myelin, the protective covering of nerve fibers. This damage disrupts nerve signal transmission. He highlighted that MS manifests in two primary forms: relapsing-remitting MS, accounting for approximately 85 percent of cases, and progressive MS, affecting around 15 percent of patients. Accurate diagnosis often involves neurological examinations, MRI scans of the brain and spinal cord, cerebrospinal fluid analysis, and nerve conduction studies. Recent advancements include the measurement of neurofilament light chains in the blood, a biomarker that can indicate nerve damage even before it’s visible on an MRI scan, according to Dr. Javidi.
Olga Pugach, a neurologist, addressed the often-overlooked psychological and neurological symptoms associated with MS. She noted that depression affects roughly 50 percent of individuals with MS, even as chronic fatigue impacts 30 to 80 percent, and cognitive impairments are present in 25 to 57 percent of cases. These cognitive deficits, which can include difficulties with processing speed, working memory, and attention, can significantly impact daily life. Early intervention and both physical and mental activity were emphasized as strategies to potentially slow the progression of these symptoms.
Latest Therapeutic Approaches on the Horizon
A key focus of the seminar was the potential of new therapies, particularly tolebrutinib. Dr. Javidi announced that tolebrutinib, a tablet specifically designed for progressive MS, is expected to receive regulatory approval in spring 2026. “This is a major step forward, as progressive MS has historically been difficult to treat,” he stated. Hephata-MVZ plans to offer the medication to patients promptly upon approval.
Beyond tolebrutinib, researchers are exploring innovative approaches like cell therapy, a technique borrowed from cancer treatment. This involves extracting a patient’s immune cells, genetically modifying them in a laboratory, and then reintroducing them to the body to target and disable the malfunctioning immune cells that cause MS. While still in the early stages of development, this approach holds promise for future treatments. Research is likewise underway to explore methods for actively repairing the myelin sheath and restoring damaged nerve fibers.
Support and Resources Available at Hephata-MVZ
Andrea Mangold, a specialized MS nurse, highlighted the comprehensive support services offered by the Hephata-MVZ’s MS consultation center. The center provides free information and counseling on the causes, symptoms, progression, and medications related to MS. They also offer guidance on navigating challenges in both professional and personal life, including understanding treatment prerequisites and potential side effects. The MS consultation center can be reached at +49 6691 182029 or via email at [email protected]. Services are available Mondays from 8 AM to 2 PM and Tuesdays through Thursdays from 8 AM to 4 PM, with additional appointments available upon request.
Hephata-MVZ will host another patient seminar on Tuesday, June 2, from 4 PM to 6 PM, focusing on Parkinson’s disease. Attendance is free and open to the public, with a complimentary light meal provided afterward. Further information can be obtained by calling +49 6691 18-2003 or emailing [email protected].
The ongoing research and evolving treatment landscape for multiple sclerosis offer renewed hope for those affected by this complex condition. Continued investigation into innovative therapies and comprehensive support services are essential to improving the lives of individuals living with MS.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for personalized guidance and treatment options.
Have you or a loved one been affected by multiple sclerosis? Share your thoughts and experiences in the comments below.
